Trial Search Results
Prostate Cancer Upgrading Reference Set
The purpose of this study is to find unique markers and clinical parameters associated with aggressive prostate cancer. We are hopeful that these new markers can be used for developing better diagnostic tests and predicting outcomes of prostate cancer. We hope to develop a risk prediction tool, to predict with at least 95% negative predictive value using all clinical, demographic, and biologic information, the lack of a higher tumor grade (i.e., Gleason 3+4 or greater) at radical prostatectomy.
Stanford is currently accepting patients for this trial.
The University of Texas Health Science Center at San Antonio
Collaborator: Emory University
1. Prostate cancer, confirmed on prostate biopsy, within two years of scheduled radical
2. Prostate cancer must be graded as Gleason 3+3 on the biopsy immediately prior to
radical prostatectomy. (Secondary eligibility will be established on central review of
pathology slides, and blocks if available, at Cornell Central Pathology Laboratory to
3. Prostate cancer may have been detected on prior biopsy as well but must not be greater
than Gleason 3+3. (Also requires Central Pathology Laboratory review.)
4. Slides must be available for Central Pathology Laboratory review on any biopsy showing
prostate cancer. FFPE Blocks may also be requested if available.
5. Patient must have selected radical prostatectomy as treatment for prostate cancer.
6. Signed informed consent.
7. Blocks and/or slides from prostate biopsy and from radical prostatectomy must be
available for analysis by Central Pathology laboratory.
8. Willingness to provide long-term follow-up information regarding additional treatments
and cancer status.
9. Willingness to provide blood and urine specimens prior to radical prostatectomy for
placement in the EDRN Upgrading Reference Set repository.
10. Willingness to provide demographic and clinical information related to prostate cancer
and prostate cancer risk (e.g., race/ethnicity, family history of prostate cancer).
1. Gleason score greater than 3+3 on any prior prostate biopsy.
2. Any treatment other than radical prostatectomy planned for prostate cancer.
3. Prior treatment of the prostate with androgen deprivation, radiation, or other
Ages Eligible for Study
35 Years - 99 Years
Genders Eligible for Study